| Read on web → |
On September 29, DEA’s Chief Administrative Law Judge stayed the broader marijuana rescheduling proceeding until he resolves a joint motion filed the day before. The motion asks him to admit a September 23 Government Accountability Office report, allow supplemental briefing and stay the case. The order does not decide any of those requests, and it does not decide Schedule III. The government’s response is due October 13. Last week’s issue said we found no new rescheduling action; that was wrong, and this issue corrects it. Elsewhere in Washington, DEA denied MedPharm Research’s application to manufacture Schedule I marijuana in bulk, and FDA exempted certain cannabinoid test systems from premarket notification. The Supreme Court declined to hear Patterson v. Michigan. In the states, Massachusetts extended its pause on new cultivator applications to June 30, 2027 and set new conditions for license extensions, a federal judge in Ohio narrowed enforcement of an in-state cultivation rule against one plaintiff, and Washington’s liquor and cannabis board agreed to start rulemaking on a medical cannabis verification certificate. Internationally, it was a light week.
This week at a glanceTop story. A DEA judge stayed the broader marijuana rescheduling proceeding on September 29, pending a motion tied to a GAO report. The government’s response is due October 13.
Next three.
- Federal: DEA denies MedPharm Research’s Schedule I bulk manufacturer application.
- Massachusetts: the CCC extends its pause on new cultivator applications to June 30, 2027.
- Ohio: a federal judge bars enforcement of an in-state cultivation rule against one plaintiff.
- Everyone: do not build tax, banking or pricing plans on an adult-use Schedule III date. The stay leaves it undecided. Calendar October 13, when the government’s response is due.
- Massachusetts licensees: if you rely on administrative extensions, confirm Department of Revenue good standing and filed returns now, and calendar December 8, 2026.
- DEA registration applicants: review your affiliates’ history with counsel before filing. The MedPharm denial turned on what related companies did.
Tell us: does the stay change your 2027 planning? Reply to this email. We read every reply, and the answers shape what we cover next.
Advertise with usWe are opening a set of promotional placements across both The Regulator Brief and cannabisregulations.ai — an array of options built to span every budget, from single-issue newsletter placements to site-wide visibility on the state legality database and blog. Slots are limited, and for now they are offered only to newsletter subscribers and early users.
Fill out the form to learn more →Federal & agency deskWhy it matters: Adult-use Schedule III remains undecided, and this order does not move it. Operators should not build tax, banking or pricing plans on a Schedule III date. The April 2026 medical-marijuana order is unaffected. Correction: Issue 020 said we found no new rescheduling action; the stay was dated September 29.
On September 29, DEA Chief Administrative Law Judge Derek C. Julius stayed the proceeding (DEA Docket 1362; Hearing Docket 26-96) “pending the Motion’s resolution.” The motion, filed September 28 by DUID Victim Voices, Kenneth Finn, M.D., and NDASA, asks to admit the September 23 GAO report, allow supplemental briefing and stay the case. GAO-26-108623 found that DEA has no written scheduling procedures and that FDA’s are incomplete; it did not find the marijuana evaluation deficient. The government’s 20-page response is due October 13.
Why it matters: The decision shows DEA weighing the unregistered activity of a company’s affiliates when it reviews a registration. It does not bar a new application under the expedited state-medical framework. Applicants with affiliated entities should talk to counsel about how their history would read.
The decision was signed October 2 by Administrator Cole and published in the Federal Register on October 7 (Doc. 2026-20553), effective 30 days after publication. MedPharm defaulted after a September 2025 Order to Show Cause. DEA found that its parent and sister company, MX, LLC, made marijuana without DEA registration for more than ten years and that the sister company sold into the recreational market, which weighed against the public interest. This is the public-inspection version; confirm the final page citation.
Why it matters: Makers and labs that supply cannabinoid tests for employment and insurance screening can use the exemption; other device requirements still apply. Companies in this lane should confirm with regulatory counsel which device classification covers their product.
FDA’s final order, 91 FR 63478, was published and took effect October 6 (Docket FDA-2026-N-4268; 21 CFR 862.3870, product code PVJ). Devices labeled solely for employment and insurance testing are exempt from 510(k). The earlier exclusion for devices used in federal drug testing programs is removed.
Why it matters: The denial resolves the item we flagged as pending last week and changes no rule. The Court gave no reasons, so it should not be read as a signal on the merits.
On October 5, the Court denied certiorari in No. 25-1263. There was no opinion, and the docket page does not show the question presented.
Why it matters: Applicants waiting on host community agreements and licensees relying on administrative extensions now have dated conditions to meet. Counsel should check each licensee’s Department of Revenue standing before the extension is needed.
On October 8, the Cannabis Control Commission voted to extend its temporary pause on new cultivator and non-majority-equity microbusiness license applications through June 30, 2027. Microbusinesses majority-owned by Social Equity Program participants or Economic Empowerment applicants are exempt (935 CMR 500.002). The bulletin does not state the extension’s effective date. In a second vote, effective October 8, administrative license extensions require Department of Revenue good standing, filed returns and a prorated fee, with a 365-day cap. Earlier delegation votes are rescinded effective December 8, 2026, and no host community agreement extensions are allowed after November 9, 2027.
Why it matters: The relief covers only the named plaintiff, so other operators cannot assume the same protection. It is still a signal that residency and in-state processing conditions are being tested in federal court.
On October 5, in Fresh Farms E Liquid v. Tischler (N.D. Ohio, No. 3:26-cv-02059), Judge Helmick modified the September 24 preliminary injunction. It bars enforcement of OAC 3796:6-3-01(C), and any other in-state cultivation or processing condition, against Fresh Farms. We reviewed the docket entry, not the full order.
Why it matters: Acceptance starts a process; it creates no program. Medical-market operators and patients should treat any certificate as a possible future rule, not a current requirement.
On October 7, all three members of the Liquor and Cannabis Board marked “Accept” on a rulemaking petition from Caitlein Ryan and The Cannabis Alliance, against staff advice to deny. No program exists yet, and we did not locate a CR-101 notice.
Why it matters: This is a data release, not a rule. It shows enforcement capacity growing, which is a useful benchmark for Illinois licensees preparing for inspections.
Released October 7, the report says IDFPR conducted 755 dispensary inspections in fiscal 2026, up from 625 in fiscal 2025, and grew its inspector count from 11 to 16. It reports no mandatory recalls and July 2026 sales above 5 million items.
Why it matters: The bill covers all drugs and has no cannabis-specific provision, so it is a signal of direction, not a change in cannabis law. It is a proposal only.
Registered October 5 and announced October 7 by Sen. Victoria Stoiciu, the bill would move personal drug possession from criminal law to administrative fines of 1,000 to 3,000 lei.
A light week internationally. Reports of German coalition amendments on medical cannabis prescribing are unconfirmed against the Bundestag text, and we are not reporting their terms.
Advertising is now open. Placements across both the newsletter and the website, with promotional options for every budget. Slots are limited — offered to newsletter subscribers and early users first. Fill out the form →
Recreational, medical, THCA, Delta-8, Delta-9, HHC, CBD, and more — cross-referenced across all 50 states plus DC and Puerto Rico. Updated as laws move. The only single source operators can use to scope multi-state compliance before drafting product, packaging, or shipping policy.
Open the state laws database →Need help with anything in this brief?Get a plain-English answer sourced to primary law, in seconds.
Open the assistant →This newsletter is not legal advice — talk to your counsel. Our directory can help you find one.
Browse the directory →One thing to readThis week’s lead concerns the broader rescheduling proceeding. Our post on the D.C. Circuit’s decision not to pause the Schedule III order for medical marijuana covers the companion track. Read the summary →
How useful was this week's brief?
Reach the people who write the compliance checks.
The Regulator Brief goes out every Monday to cannabis attorneys, compliance officers, and licensed operators across US states and international jurisdictions. If you want to put your product in front of them, get in touch.
Know someone who'd benefit from this?
Forward it, or use your personal link below. Refer three colleagues and we'll send you our 50-state cannabis legality reference PDF.

